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The papillary tumor of the pineal region (PTPR) is a rare grade II-III pineal lesion with peculiar histologic and 
immunohistochemical features. These tumors mostly occur in adults, rarely in children (19 cases reported up to 
now). 
We present a 3-year-old boy who was re-operated for a recurrent PTPR (grade II). The gross total resection of 
the lesion, through an occipital interhemispheric approach in sitting position, was followed by adjuvant 
radiochemotherapy. Histological examination revealed tumor progression (grade III), and the MIB-1 
proliferation index was higher than 25%. The patient continues to do well with no evidence of recurrence more 
than 3 years following surgery. 
A comprehensive literature review regarding the PTPR, including the current management in children, is 
reported. 
PTPR are extremely rare in children, and immunohistchemistry is needed for their differentiation from other 
pineal tumors. These tumors present a big rate of rcur ence, and a multidisciplinary management (microsurgical 
resection followed by radio- and/or chemo-therapy) is needed in most of the cases to achieve favorable 
outcomes. 
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The papillary tumor of the pineal region (PTPR) is a new entity introduced in the 2007 World Health 
Organization nomenclature to describe a rare grade II-III pineal lesion with particular histologic and 
immunohistochemical features. These tumors mostly occur in the adult population, and are extremely rare in 
children.1–3 
Herein, we present the case of a 3-year-old boy who as initially operated abroad for acute hydrocephalus due to 
a PTPR, and then, after few months, was admitted to our department for a tumor recurrence. 
Our purpose is to report the multidisciplinary management of this case, which presented a good response after 
the gross total resection of the lesion and adjuvant r diotherapy and chemotherapy, with no recurrence after 3 
years. 
Moreover, we present a comprehensive literature review regarding the PTPR while describing the current 
management of this new entity in children. 
 
Case presentation  
A three-year-old boy with a grade II PTPR was admitted to our department for re-evaluation. Nine months prior, 
he presented with acute hydrocephalus, and underwent subtotal resection of the lesion abroad. Follow up brain 
MRI revealed the persistence of a giant heterogeneously enhancing pineal region lesion with a small cystic 
component (Fig. 1). Ventriculomegaly was also present. The boy did not present neurological deficits. 
The patient underwent an occipital interhemispheric approach in sitting position with gross total tumor resection 
(Fig. 1). The postoperative course was uneventful.  
Based on the operative video analysis, microsurgical aspects may be detailed as follows: 
• after a left occipital craniotomy, the dura is opened under the microscope based on the superior 
longitudinal sinus;  
• strong dural retraction with vicryl stitches along the opening provides a hemostasis of the epidural 
space; 
• the cerebrospinal fluid is released from the posterior interhemispheric cistern along the interhemispheric 
approach; 
• after a careful access the tumor is recognized, and, under a high magnification, tissue samples are tak n 
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• internal debulking of the tumor is performed using ring forceps and long bipolar forceps as well; 
• small vessels running on the surface of the tumor are coagulated and cut. After a careful dissection and 
devascularization of the lesion, the tumor is softly but constantly pulled out using long ring 
microforceps in the right hand and thumb regulated suction tube in the left hand;  
• the tumor is shrunk with bipolar coagulation, and a piecemeal reduction of the tumor is performed;  
• water dissection is used to separate deep borders of the lesion from the surrounding tissue, and 
continuos irrigation as well is used to keep a clean surgical field; 
• the final steps include a painstaking detachment of tumoral remnants from the inferior sagittal sinus, 
and a meticulous hemostasis of the surgical site. 
After surgery, the histologic diagnosis was grade III PTPR. According to immunohistochemistry, the lesion was 
positive for pancytokeratins (Cytokeratin 5,6,8,18) vimentin, microtubule associated protein 2 (MAP 2), S100 
protein, integrase interactor 1 (INI-1), CD99, transthyretin, CD56, epithelial membrane antigen (EMA, focal 
positivity), and synaptophysin (weak focal positivity). On the other hand, the lesion was negative for 
neurofilament protein (SMI-32), glial fibrillary acidic protein (GFAP), and chromogranin A (Fig. 2). 
The MIB-1 proliferation index was higher than 25%, and the mitosis-specific marker phosphohistone-H3 
(PHH3) determined 15 mitosis/mm2. Compared with the previous histologic result from the first surgery, this 
tumor recurrence had more necrosis, more mitosis, and the MIB-1 proliferation index was higher too.  
Four weeks after the surgery, the patient received focal fractionated radiotherapy of the pineal tumor bed. A total 
of 54Gy was divided in a daily dose of 1,8Gy. In February 2015, the patient started chemotherapy based on an 
ependymoma protocol of cisplatin-cyclophosphamide-vincristine-etoposide, which was delivered in four 
intravenous cycles, each lasting 21 days: 1) days 1, 8, and 15 for the first three cycles: vincristine, 1.5 mg/m², 2) 
days 1, 2, 3: etoposide, 100 mg/m², 3) day 1: cisplatin, 100 mg/m², and 4) days 2, 3: cyclophosphamide, 1000 
mg/m².4 The cisplatin dose had to be reduced from 100mg/m2 to 80mg/m2 because the patient had only one 
kidney for a congenital malformation.  
The patient continues to do clinically well with noevidence of developmental delay and without recurrence more 
than 3 years following surgery (Fig.1). 
 
Discussion and literature review 
The PTPR is a grade II-III pineal lesion introduced in the 2007 World Health Organization nomenclature, with 
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According to the French Register of pineal tumors, true pineal tumors represent: pineal parenchymal tumors 
(27%), germ cell tumors (27%), gliomas (17%), and papillary tumors (8%). Pineal parenchymal tumors are 
represented by: pineocytomas (13%), pineal parenchymal tumors with intermediary differentiation (66%), and 
pinealoblastomas (21%).5  
The first pineal tumor with a papillary aspect, reported as papillary pineocytoma, was described by Trojanowski 
in 1982.6 In 2003, Jouvet et al. introduced the term “PTPR”.7  
Other pineal region tumors with expression of papill ry features comprise: ependymoma, choroid plexus tumor, 
papillary meningioma, germ cell tumor, and papillary metastatic carcinoma6  
It is currently believed that the PTPR could derive from the subcommissural organ; thus, PTPR, as well as the 
ependymal cells arising from the subcommissural organ itself, highly express cytokeratin 18 (CK18).7–9  
 
Histology 
PTPR are tumors characterized by an epithelial-like growth pattern in which vessels are covered by a layer of 
tumor cells forming perivascular pseudorosettes.10,11 Light microscopy shows a papillary architecture; vascular 
connective tissue is composed of several layers of large cuboidal or columnar epithelial-like growth pattern 
cells.9 Cells’ cytoplasm is clear, and sometimes vacuolated. Nuclei are small and rounded. Mitotic figures are 
rare and areas of tumor necrosis are very frequent.7,11,12 PTPR cannot be diagnosed by light microscope, thus
immunohistochemical tumor profiles must be acquired.10  
 
Immunohistochemistry 
Cytokeratin KL1 and cytokeratin 18 are constantly expr ssed by PTPR. PS100, vimentin, and neuron-specific 
enolase are frequently positive as well. Transthyretin, synaptophysin, and chromogranin immunolabeling are 
inconstantly positive. Tumor cells do not express GFAP nor EMA, but GFAP expression would be recognized in 
the perivascular areas of the tumor.7,12 Immunolabeling for antineural cell adhesin molecul and nestin is 
frequently positive, but immunolabeling for anti-NF, anti-antigen S, anti-tau protein, anti-α- fetoprotein, and 
anti-placental alkaline phosphatase antibodies is negative.7  
Some studies determined that phosphatase and tensin homolog (PTEN) mutations and activation of the 
PI3K/Akt/mTOR signaling pathway may play a role in the biology of PTPR, thus opening the possibility to the 
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Regarding chromosomal alterations, losses of chromos e 10 were very frequent in different studies. Losses of 
chromosomes 3, 14, 22, and X were also identified; and gains of chromosomes 8, 9, and 12 were common, as 
well. Other chromosomal alterations include a homozyg us PTEN deletion, and 2 point mutations in exon 7 of
PTEN (G251D and Q261stop).13,14 Fèvre-Montange reported that PTPRs showed high expression of SPDEF, 
KRT18, and genes encoding proteins reported to be expressed in the subcommissural organ, such as ZFH4, 
RFX3, transthyretin, and CGRP.15  
 
Imaging 
Chang et al. reported an intrinsic T1 hyperintensity centered on the posterior commissure, associated with T2 
hyperintensity and gadolinium enhancement as a regular presentation in 4 PTPRs.16 However, fat content related 
to teratomas, as well as melanin, calcification and extracellular methemoglobin, usually seen in melanotic 
tumors, and hemorrhagic metastases, choriocarcinomas or teratomas, must also be excluded.17 Opposite to this 
description, other authors just reported MRI heterog neous mass isointense on T1.10  
 
The biological behavior of PTPRs 
PTPRs grading and prognosis are still unclear so far, and reports of long survival cases contrast with those with 
local tumor recurrence. Histological grading of PTPRs correspond to WHO grade II or III.1,2,18 Variables related 
to decreased progression-free survival are represent d by: more than 3 mitoses per 10 high-powered fiel s, or a 
Ki-67 proliferation index of more than 10%.14,19 Some authors reported the isocitrate dehydrogenase 1 and 2 
mutations in PTPR cells as a predictor of wild-type genotypes, as similarly described in gliomas.20  
 
Differential diagnosis 
Regarding to the differential diagnosis, as mentioned above, different tumors present papillary architecture. 
However, the two main differential diagnoses are: papillary ependymomas, and choroid plexus tumors. Choroid 
plexus tumors share with PTPR a comparable immunohist chemical profile, but with a different morphologic 
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expression. Choroid plexus tumors present exclusively papillary architecture lined by a single cell layer without 
the massive component, and, unlike PTPR, areas of necrosis are extremely rare. Choroid plexus carcinomas are 
well differentiated and with higher degree of aplasia. Regarding the immunohistochemical analysis, potassium 
inwardly-rectifying channel Kir 7.1 and stanniocalcin-1 are only expressed by choroid plexus tumors.21 
Ependimomas show a constant expression of EMA and GFAP, with no expression of cytokeratin KL1.12 Finally, 
only papillary tumors express MAP 2.21  
Papillary meningiomas, in contrast with PTPR, present a dense membrane expression of EMA. Vimentin and 
protein S100 are expressed by papillary meningiomas in 40% of cases. Papillary tumors of the pineal 
parenchyma, such as papillary pineocytoma, present massive expression of synaptophysin and antigen S, while 
cytokeratins and vimentin are not expressed.21  
DNA methylation profiling using Illumina 450k arrays reliably distinguished PTPR from ependimomas and 
pineal parenchymal tumors of intermediate differentiation. The group of PTPR with a higher global methylation 
had a tendency toward shorter progression-free survival.14 The overexpressed SPDEF gene, known to be present 
in the rodent subcommissural organ, has a remarkable expression in PTPR compared with ependymal tumors, 
choroid plexus tumors, and samples of other central ervous system tumor entities.14 Some papillary tumors of 
the midline, such us papillary thyroid carcinoma and papillary craniopharyngioma, conceal BRAF-V600E 
mutations. However, PTPR demonstrated negativity for BRAF-V600E.22  
 
Management 
In a multicentric retrospective study of 31 patients by Fèvre-Montange et al., gross total resection was the only 
factor that tended to have a significant positive eff ct on disease progression. A complete open resection was 
achieved in 21 cases and, after heterogeneous schemes of radiotherapy after complete (9) or incomplete (6) 
resection, 21 patients presented local (19), local and spinal (1), or only spinal (1) progression in a mean follow 
up of 4.2 years (range, 0.2–16.5 years). The overall survival was 73% at 5 years, and 58% at 10 years.11  
Regarding to the radiotherapy, based on the above-mentioned study, this tumor appears to have a high potential 
for local recurrence during the 5 years after initial surgery, suggesting the need for tumor bed boost radiotherapy 
after surgical resection. However, no strong evidence is available. On the other hand, spinal disseminatio  seems 
to be rare.11,12  
Radiotherapy may consist of craniospinal irradiation with a boost to the primary site, whole brain radiotherapy 
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by Fauchon, the median pineal dose in 22 of the 26 irradiated cases was 54 Gy (CI 95 %: 12.0–60.0 Gy).Despite 
relatively high cumulative doses (more than 100 Gy in 3 cases), only 2 cases presented irradiation-related side 
effects: a thalamic radionecrosis associated with diplopia and hypersomnia, and a thalamo-tectal radionecrosis 
associated with motor deficiency and Parinaud’s syndrome.23  
Some authors reported favorable outcomes after biopsy procedures followed by radiotherapy. In a case reported 
by Smruti, an endoscopic third ventriculostomy with a simultaneous endoscopic biopsy followed by 
postoperative radiotherapy (50.4 Gy) resulted in a complete regression of the tumor with no evidence of 
recurrence at 25 months.24 Similarly, Riis et al. described a case of a PTPR treated with stereotactic radiosurgery 
in a Gamma Knife unit after stereotactic biopsy of the tumor. Five years after treatment with a dose of 12 Gy on 
the 50% isodose, the tumor size was still decreasing.25 
Ishida et al. studied the safety and efficacy of stereotactic 125iodine brachytherapy for the treatmen of PTPRs. 
100% local tumor control was achieved with a median follow-up of more than four years. No significant clinical 
nor radiological side effects of 125iodine brachytherapy were detected during the follow-up period, and ll 
symptoms improved significantly.20,26  
Chemotherapy has been proposed in specific cases: rapid spinal dissemination, first-line radiotherapy based 
treatment, and in patients with local recurrences. However, the evidence remains weak to support this modality 
treatment.21 Adjuvant chemotherapy is mainly based on cisplatinum and etoposide protocols. Those referred in 
the literature include: carboplatin-VP16- vincristine, carboplatin plus either etoposide or vincristine, 
temozolomide and, ACNU (3-[(4-amino-2-methyl-5-pyrimidinyl) methyl]- l-(chloroethyl)-l-nitrosourea) 
chemotherapy.10,23,27–29 Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth 
factor, which has demonstrated activity in ependymoma, should be considered for inoperable recurrent PTPR, or 
in those amenable/responsive to radiation or standard cytotoxic treatments.30,31  
 
Papillary tumor of the pineal region in children 
Regarding to the management of PTPRs in children, even though the proportion of PTPRs between children and 
adult population is suggested to be between 16-19%, the literature is scarce.11,22 Table 1 lists the published 
cases.10–12,22,23,32–37 We found 19 cases in children younger than 17 years old. Although some information was 
not available in this small population of cases, some conclusions from all 20 patients could be outlined. No 
difference regarding the sex was found, and the mean diameter of the tumor was 30 mm. In 3 cases, unavailable 
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months. 8/17 (47%) patients had a tumor recurrence or r growth during the follow up. The mean time of the first 
recurrence was 34.5 (10-60) months. At the last follow up, 15/17 (88%) patients were alive and symptom free or 
with controlled disease, while one patient had a progressive disease after 115 months, and another pati nt died 
61 months after starting the treatment. A gross total resection along the course of the disease was performed in 
15/17 (88%) cases, while in the remaining two cases (12%) a partial resection followed by radio and 
chemotherapy was carried out, with stable disease after 15 and 21 months. Only 3 (20%) of the 15 patients who 
underwent a gross total resection did not receive complementary therapy during the course of the disease. 
Concurrently, those cases did not recur during 3, 12, and 15 months of follow up.10–12,22,23,32–37  
Summarizing our results, 17 out of 20 pediatric patients in the literature had follow-up information, and a gross 
total resection was achieved in 15 of them along the course of the disease. Only one of the two patients with 
partial resection had a non-recurrent stable disease.. Four of the 8 patients who presented a local 
recurrence/regrowth during the follow-up, had a second recurrence (3 local recurrences, and one spinal a d 
ventricular recurrence). Three cases recurred three times (a repeated spinal recurrence, a local recurnce, and 
another ventricular recurrence). One patient had 4 local recurrences of the disease. The unique patient with 
spinal disease died.10–12,22,23,32–37  
Compared to the epidemiology in the general population, where 68% of PTPR recurred in a mean follow up of 
4.2 years (with an overall survival of 73% at 5 years, nd 58% at 10 years), in children population only the 47% 
of PTPR recurred in a mean follow up of 6,5 years.11 The survival rate of the entire children group was 94% with 
only one dead patient 5 years after starting the treatment. However, only 40% of the kids had a follow up over 5 
years.11 This difference could be explained by the fact thaa gross total resection was achieved in 88.24% of the 
pediatric cases and only in the 68% of the adults. However, the reason could be also found in a different, more 
aggressive and infiltrative biological behavior of the tumor in adults. In this regard, measurements of he DNA 
methylation, determination of the isocitrate dehydrogenase 1 and 2 mutations in PTPR cells, over the well-
known mitotic and Ki-67 proliferation index, could represent important tools for evaluating the progression-free 
survival rate. Moreover, future perspectives on genetic features will be essential to determine the malign ncy 
grade of the lesion.14,19,20  
Surgery was performed by different approaches: the occipital interhemisferic, the suboccipital supracerebellar, 
the traschoroidal, and the endoscopic translaminar terminalis represented the main used routes.10–12,22,23,32–37 
Regarding the posterior routes to the pineal regions, the sitting position may offer several advantages over the 
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major complications.38–45 Biopsy through an endoscopic approach, associated with a third ventriculostomy, 
followed by radiotherapy was an option too. Whatever approach is selected, skillful and clean 
microneurosurgery preserving the normal anatomy is imperative during pineal region operations. 35,44–47 
Common radiotherapy schemes included external beam radiotherapy, and proton beam radiotherapy with doses 
of 50-54 Gy as a part of the initial treatment and treatment for the recurrences. 10–12,22,23,32–37 A local recurrence in 
a 13 years old boy (who initially underwent a gross-total resection, craniospinal radiation, and chemotherapy) 
was controlled by a partial resection followed by stereotactic radiosurgery (20 Gy). The patient had subsequently 
other two local resections that were managed with stereotactic radiosurgery alone (22, and 20Gy). At 180 
months follow-up the patient is able to work as a computer scientist.36  
The main schemes of chemotherapy were based on ACNU, Carboplatine-VP16-vincristine, 9 cycles of 
gemcitabine–oxaliplatine as second line chemotherapy for the case with the spinal recurrence, and cisplatin-
cyclophosphamide-vincristine-etoposide in our case.10–12,22,23,32–37 
 
Conclusion 
Even though PTPRs in children have a big rate of recur nce during the first 5 years, they have a good control of 
the disease. Radiotherapy and chemotherapy are important tools in the management of the disease, as well as of 
their recurrences after gross total resection. Stereo actic radiosurgery might be an important tool for the 
management of local recurrences of the tumor with good cognitive function at long term follow-up.  
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Fig.1 Sagittal cerebral MRI scans. Preoperative MRI showing a pineal lesion (A), which underwent a subtotal 
resection abroad (B). The histologic diagnosis was a grade II papillary tumor of the pineal region. 9 months MRI 
revealing a regrowth of the tumor (C). The patient u derwent an occipital interhemispheric approach wit  gross 
total removal at our department (D), followed by adjuvant radiochemotherapy. Histological examination 
revealed tumor progression (grade III). The patient continues to do well with no evidence of recurrence more 
than 3 years following surgery (E) 
 
Fig.2 Photomicrographs of surgical specimens. Hematoxylin and eosin staining showing an epithelial-like 
growth pattern with vessels covered by a layer of tumor cells forming perivascular pseudorosettes (A).Some 
necrotic areas were present (B). Immunohistochemistry was positive for pancytokeratins (C), cytokeratin 18 (D), 
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*These cases were published initially by Fèvre-Montange et al.11, and later updated by Fauchon et al.23  
§One case was also reported by Jeruc and Popovic with no available information in the literature 
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ACNU, nimustina; B, biopsy; Ca, carboplatine; Ci, cisplatin; CMT, chemotherapy; Cy, cyclophosphamide; E, etoposide; ETV, endoscopic third ventriculostomy; GEMOX, gemcitabine–
oxaliplatine; GKRT, gamma knife radiation therapy; GTR, gross-total resection; HPF, high-power field; LR, local recurrence; M, methotrexate; MI, mitosis; NAI, not available 
information; OC, occipital craniotomy; OIH, occipital interhemispheric approach; PBRT, proton-beam radiation therapy; PR, partial resection; RT, radiotherapy; SCIT, supracerebellar 
infratentorial approach; SOA, suboccipital approach; SOTA, suboccipital transtentorial approach; SR, spinal recurrence; SRS, stereotactic radiosurgery; TFCA, transfrontal transchoroidal 









































Papillary tumor of the pineal region in children: presentation of a case and comprehensive literature review 
 
Highlights 
Papillary tumors of the pineal region (PTPRs) are rare grade II-III pineal lesions 
Immunohistochemistry is needed for their differentiation from other pineal tumors 
We describe a successful multidisciplinary management of a PTPR in a 3-year-old boy 
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